1ZTX
West Nile Virus Envelope Protein DIII in complex with neutralizing E16 antibody Fab
1ZTX の概要
| エントリーDOI | 10.2210/pdb1ztx/pdb |
| 分子名称 | Envelope protein, Heavy Chain of E16 Antibody, Light Chain of E16 Antibody, ... (4 entities in total) |
| 機能のキーワード | antibody, fab, neutralizing, virus, envelope, viral protein-immune system complex, viral protein/immune system |
| 由来する生物種 | West Nile virus 詳細 |
| 細胞内の位置 | Envelope protein E: Virion membrane; Multi- pass membrane protein: Q91KZ4 |
| タンパク質・核酸の鎖数 | 3 |
| 化学式量合計 | 58140.67 |
| 構造登録者 | Nybakken, G.E.,Oliphant, T.,Diamond, M.S.,Fremont, D.H. (登録日: 2005-05-27, 公開日: 2005-10-04, 最終更新日: 2024-10-30) |
| 主引用文献 | Nybakken, G.E.,Oliphant, T.,Johnson, S.,Burke, S.,Diamond, M.S.,Fremont, D.H. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature, 437:764-769, 2005 Cited by PubMed Abstract: West Nile virus is a mosquito-borne flavivirus closely related to the human epidemic-causing dengue, yellow fever and Japanese encephalitis viruses. In establishing infection these icosahedral viruses undergo endosomal membrane fusion catalysed by envelope glycoprotein rearrangement of the putative receptor-binding domain III (DIII) and exposure of the hydrophobic fusion loop. Humoral immunity has an essential protective function early in the course of West Nile virus infection. Here, we investigate the mechanism of neutralization by the E16 monoclonal antibody that specifically binds DIII. Structurally, the E16 antibody Fab fragment engages 16 residues positioned on four loops of DIII, a consensus neutralizing epitope sequence conserved in West Nile virus and distinct in other flaviviruses. The E16 epitope protrudes from the surface of mature virions in three distinct environments, and docking studies predict Fab binding will leave five-fold clustered epitopes exposed. We also show that E16 inhibits infection primarily at a step after viral attachment, potentially by blocking envelope glycoprotein conformational changes. Collectively, our results suggest that a vaccine strategy targeting the dominant DIII epitope may elicit safe and effective immune responses against flaviviral diseases. PubMed: 16193056DOI: 10.1038/nature03956 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.5 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






